Elmucin (erdosteine) 300 mg
English product name
Elmucin
Release Form
Capsules
Description Elmucin
The capsules are solid gelatine, №1, with a body and a cap of yellow color; the contents of the capsules are white or almost white powder.
1 cap.
erdosteine 300 mg
Auxiliary substances: microcrystalline cellulose, C30 povidone, magnesium stearate.
Capsule body and lid composition: titanium dioxide, quinoline yellow dye, sunsetting yellow dye, gelatin.
10 pcs. - packages of contour compartments (1) - cardboard packs.
10 pcs. - packages of contour compartments (2) - cardboard packages.
10 pcs. - packages of contour compartments (3) - cardboard packages.
10 pcs. - packages of contour compartments (4) - cardboard packages.
20 pcs. - packages of contour compartments (1) - cardboard packs.
20 pcs. - packages of contour compartments (2) - cardboard packages.
20 pcs. - packages of contour compartments (3) - cardboard packages.
20 pcs. - packages of contour compartments (4) - cardboard packages.
ATC codes
R05CB15 Erdosteine
Clinical-pharmacological groups / Group affiliation
Mucolytic preparation
Active substance
erdosteine
Pharmaco-therapeutic group Elmucin
Expectorant mucolytic agent
Pharmacological effect Elmucin
Mucolytic agent. The efficiency of erdosteine is due to the action of active metabolites. Thiol groups of metabolites cause disulfide bridges to rupture, which bind one to the other glycoprotein fibers, leading to a reduction in the elasticity and viscosity of the sputum. As a result, erdosteine enhances and accelerates the release of respiratory tract secretions from secretion, improves the secretory function of epithelium and increases the effectiveness of mucociliary transport in the upper and lower sections of the respiratory tract.
Testimony Elmucin
- Respiratory tract diseases with formation of viscous sputum:
- acute and chronic bronchitis;
- pneumonia;
- COPD;
- bronchial asthma with difficulty of sputum withdrawal;
- bronchoectic disease;
- prevention of pneumonia and lung atelectasis after surgical interventions.
Method of use, course and dosage Elmucin
Taken inside. The recommended dose is 300 mg two to three times a day. If the patient does not improve within five days after the start of the application or if the condition worsens, he or she will have to see a doctor.
- Nosology (ICD codes)
- J15
- Bacterial pneumonia not classified elsewhere
- J20
- Acute bronchitis
- J42
- Chronic bronchitis unspecified
- J44
- Other chronic obstructive pulmonary disease
- J45
- Asthma
- J47
- Bronchiectasis
- R09.3
- Mokrota
